IP Library › Granted Patent US 10,590,468
Granted Patent B2
US 10,590,468 · App. 15/315,931 · Granted Mar 17, 2020

Method for methylation analysis

Inventors: Susanne Pedersen (New South Wales, AU); Rohan Baker (New South Wales, AU)
Assignee: CLINICAL GENOMICS PTY LTD
C12Q1/6827C12Q1/6886C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,590,468
App. No.
15/315,931
Granted
Mar 17, 2020
Kind
B2
Abstract

The present invention relates generally to a method for assessing nucleic acid methylation, in particular DNA and RNA methylation. More particularly, the present invention relates to a method of either qualitatively or quantitatively assessing, with improved sensitivity, the cytosine methylation of partially methylated DNA or RNA. The method of the present invention is useful in a range of applications including, but not limited to, the diagnosis of conditions or monitoring of developmental phenotypes which are characterised by DNA or RNA methylation changes.

Claims (64)

1. A method for detecting the cytosine methylation of a nucleic acid target of interest, said method comprising:

(i) contacting a nucleic acid sample with an agent which modifies unmethylated cytosine residues;

(ii) measuring within a single reaction, regions of partial methylation in a DNA form of the nucleic acid sample of step (i) by contacting the DNA with:

(a) a primer set comprising forward and reverse primers designed to amplify one or more partially methylated forms of a region of cytosine methylation; and

(b) one or more probes directed to said region of cytosine methylation wherein said one or more probes are capable of collectively hybridising to at least two differing methylation patterns at said region and wherein said probe comprises a detectable moiety;

(iii) amplifying the sample of step (ii), wherein the extension of said primers along said target of interest effects the detection of said hybridised probe; and,

(iv) qualitatively or quantitatively analysing the detection output of step (iii).

2. The method according to claim 1 , wherein said nucleic acid target of interest is a DNA or RNA gene or gene region.

3. The method according to claim 2 , wherein said gene region is a promoter region.

4. The method according to claim 2 , wherein said gene is a mammalian gene.

5. The method according to claim 2 , wherein said gene is a large intestine neoplasm marker.

6. The method according to claim 5 , wherein said large intestine neoplasm marker is the gene BCAT1, IKZF1, IRF4, GRASP, CAHM, SOX21, SLC6A15, NPY, ST8SIA1, ZSCAN18, COL4A2, DLX5, FGF5, FOXF1, FOXI2 or SDC2, wherein said gene includes 5 kb upstream of the transcription start site.

7. The method according to claim 6 , wherein said gene is IKZF1.

8. The method according to claim 7 , wherein said method comprises detecting methylation at one or more of the Chr7:50304323-50304349, Chr7:50303300-50304923 or Chr7:50399869-50400702 regions of the IKZF1 gene.

9. The method according to claim 1 , wherein said DNA is genomic DNA.

10. The method according to claim 1 , wherein said agent modifies unmethylated cytosine residues to uracil.

11. The method according to claim 10 , wherein said agent is a bisulphite salt.

12. The method according to claim 11 , wherein said bisulphite salt is sodium bisulphite or ammonium bisulphite.

13. The method according to claim 1 , wherein said primers are methylation specific primers.

14. The method according to claim 1 , wherein said probes are hydrolysis probes.

15. The method according to claim 1 , wherein said probes collectively hybridise to all full and partial methylation patterns at said region.

16. The method according to claim 1 , wherein said nucleic acid target is IKZF1 and the primer set includes primers which comprise one or more of:

(i) the SEQ ID NO:3 and SEQ ID NO:4 sequences or a sequence exhibiting at least 95% identity;

(ii) the SEQ ID NO:49-62 and SEQ ID NO:63-76 sequences or a sequence exhibiting at least 95% identity; or

(iii) the SEQ ID NO:77 and SEQ ID NO:78 sequences or a sequence exhibiting at least 95% identity.

17. The method according to claim 1 , wherein said nucleic acid target is IKZF1 and the probe set includes probes which comprise one or more of:

(i) the SEQ ID NO:5-12 sequences or a sequence exhibiting at least 95% identity;

(ii) the SEQ ID NO:19 sequence or a sequence exhibiting at least 95% identity;

(iii) the SEQ ID NO:20 sequence or a sequence exhibiting at least 95% identity; or

(iv) the SEQ ID NO:23-30 sequences or a sequence exhibiting at least 95% identity.

18. The method according to claim 1 , wherein said nucleic acid target is IKZF1, said DNA of step (ii) is a bisulfite converted DNA strand that is the complement of SEQ ID NO:1 and the primer set includes primers which comprise one or both of the SEQ ID NO:47 and SEQ ID NO:48 sequences or a sequence exhibiting at least 95% identity.

19. The method according to claim 1 wherein said nucleic acid target is IKZF1, said DNA of step (ii) is a bisulfite converted DNA strand that is the complement of SEQ ID NO:1 and the probe set includes probes which comprise one or more of:

(i) the SEQ ID NO:21 sequence or a sequence exhibiting at least 95% identity;

(ii) the SEQ ID NO:22 sequence or a sequence exhibiting at least 95% identity;

(iii) the SEQ ID NO:31-38 sequences or a sequence exhibiting at least 95% identity; and/or the SEQ ID NO:39-46 sequences or a sequence exhibiting at least 95% identity.

20. A diagnostic kit for detecting the cytosine methylation of a region of a nucleic acid target of interest, said kit comprising:

(i) a primer set comprising forward and reverse primers designed to amplify one or more partially methylated forms of a DNA form of said nucleic acid region in which unmethylated cytosine residues have been modified, wherein the primer set includes primers which comprise a sequence as set forth in:

(a) SEQ ID NO: 3 and SEQ ID NO: 4 or a sequence exhibiting at least 95% identity;

(b) SEQ ID NO: 47 and SEQ ID NO: 48 or a sequence exhibiting at least 95% identity;

(c) SEQ ID NOs: 49-62 and SEQ ID NOs: 63-76 or a sequence exhibiting at least 95% identity; or

(d) SEQ ID NO: 77 and SEQ ID NO: 78 or a sequence exhibiting at least 95% identity; and

(ii) one or more probes directed to the regions of partial cytosine methylation of the DNA of step (i) which probes are capable of collectively hybridising to at least two differing methylation patterns, wherein the one or more probes include probes comprising a sequence as set forth in:

(a) SEQ ID Nos: 5-12 or a sequence exhibiting at least 95% identity;

(b) SEQ ID NO: 19 or a sequence exhibiting at least 95% identity;

(c) SEQ ID NO: 20 or a sequence exhibiting at least 95% identity;

(d) SEQ ID NO: 21 or a sequence exhibiting at least 95% identity;

(e) SEQ ID NO: 22 or a sequence exhibiting at least 95% identity;

(f) SEQ ID NOs: 23-30 or a sequence exhibiting at least 95% identity;

(g) SEQ ID NOs: 31-38 or a sequence exhibiting at least 95% identity; or

(h) SEQ ID NOs: 39-46 or a sequence exhibiting at least 95% identity.

21. The kit according to claim 20 , wherein said primers are methylation specific primers.

22. The kit according to claim 20 , wherein said probes are hydrolysis probes.

23. The kit according to claim 20 , wherein said probes collectively hybridise to all of the full and partial methylation patterns of said region.

24. The kit according to claim 20 , wherein said kit additionally comprises an agent which modifies unmethylated cytosine residues.

25. The kit according to claim 24 , wherein said agent is a bisulphite salt.

26. The kit according to claim 25 , wherein said bisulphite salt is sodium bisulphite or ammonium bisulphite.

27. The kit according to claim 20 , wherein said kit additionally comprises reagents to effect DNA amplification and/or detection.

28. The kit according to claim 20 , wherein said nucleic acid target of interest is IKZF1.

29. The kit according to claim 28 , wherein said primers and probes are directed to detecting methylation at one or more of the Chr7:50304323-50304349, Chr7:50303300-50304923 or Chr7:50399869-50400702 regions of the IKZF1 gene.

30. The kit according to claim 1 , wherein said nucleic acid target is IKZF1, and the primer set includes primers which comprise one or both of the SEQ ID NO:47 and SEQ ID NO:48 sequences or sequence exhibiting at least 95% identity.

31. The kit according to claim 28 , wherein said nucleic acid target is IKZF1, and the one or more probes comprise one or more of:

(i) the SEQ ID NO:21 sequence or a sequence exhibiting at least 95% identity;

(ii) the SEQ ID NO:22 sequence or a sequence exhibiting at least 95% identity; or

(iii) the SEQ ID NO:31-38 sequences or a sequence exhibiting at least 95% identity; and/or the SEQ ID NO:39-46 sequences or a sequence exhibiting at least 95% identity.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2017
From: PEDERSEN, SUSANNE; BAKER, ROHAN
To: CLINICAL GENOMICS PTY LTD
Reel/Frame 041452/0992 →
Priority Claims (1)
AU 2014902155 · Jun 5, 2014 · national
Continuity (1)
Related Publication 20170145485A1 · May 25, 2017
Cited By (5)
US 12,512,183 US 12,516,385 US 12,571,039 US 12,624,394 US 12,706,180